COVID19 Immunology and Omics Study

Overview

About this study

The purpose of this study is to enumerate dendritic cells, to measure IFN-a production by pDC, and to measure cytokines, growth factors, proteins and metabolites/lipids, and to develop a predictive laboratory score for stratifying COVID-19+ individuals into subgroups with different prognoses and therapeutic needs. 

Plasmacytoid dendritic cells (pDCs) specialize in producing type I interferons (IFN-I). As such, they play an important role as an early line of defense against viral infections.

The majority of COVID-19+ individuals follow an uncomplicated course, with a smaller subset of patients requiring hospitalization or intensive care level support.

Early pDC enumeration in the peripheral blood and assessment of IFN-a could help predict outcomes of COVID-19+ individuals.

Additional assessment of cytokines, growth factors, proteins (including complement proteins, clotting factors, adhesion molecules, matrix proteins, receptors, lectins, and tissue injury factors) and metabolites/lipids in COVID-19+ individuals would enable an accurate understanding of the pathophysiology of different complications observed in patients infected with SARS-CoV-2 during the inflammatory state of the disease (e.g. myocarditis, acute renal disease, thrombosis).

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adult patients ≥ 18 years old.
  • COVID-19+ and COVID-19- individuals (controls), as determined by qPCR.

Exclusion Criteria:

  • Individuals < 18 years of age.
  • Pregnant women.
  • Individuals with ambiguous COVID-19 result by qPCR.
  • Individuals who have received one, or both doses of the Covid 19 vaccine.
  • Individuals who are recieving a monoclonal antibody infusion.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Amir Sadighi Akha, M.D., D.Phil.

Open for enrollment

Contact information:

Katelyn Reed B.S., M.H.S.

(507) 284-0503

Reed.Katelyn@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20503574

Mayo Clinic Footer